Berenberg Bank Reaffirms “Buy” Rating for NIOX Group (LON:NIOX)

NIOX Group (LON:NIOX)‘s stock had its “buy” rating restated by equities researchers at Berenberg Bank in a report issued on Tuesday, Marketbeat.com reports. They presently have a GBX 90 ($1.19) target price on the stock. Berenberg Bank’s target price suggests a potential upside of 52.54% from the stock’s previous close.

NIOX Group Price Performance

NIOX opened at GBX 59 ($0.78) on Tuesday. The firm has a 50-day moving average price of GBX 65.61 and a 200-day moving average price of GBX 63.93. NIOX Group has a twelve month low of GBX 53.40 ($0.71) and a twelve month high of GBX 80 ($1.06). The company has a quick ratio of 1.94, a current ratio of 6.31 and a debt-to-equity ratio of 1.10. The company has a market capitalization of £24.23 billion, a price-to-earnings ratio of 2,434.83 and a beta of 0.92.

NIOX Group (LON:NIOX) last issued its earnings results on Tuesday, April 1st. The company reported GBX 2.27 ($0.03) earnings per share (EPS) for the quarter. NIOX Group had a net margin of 28.21% and a return on equity of 13.29%. Equities analysts expect that NIOX Group will post 1.1658256 EPS for the current year.

Insiders Place Their Bets

In other NIOX Group news, insider Jonathan Emms acquired 127,454 shares of the business’s stock in a transaction dated Tuesday, April 1st. The stock was bought at an average price of GBX 8 ($0.11) per share, with a total value of £10,196.32 ($13,496.12). 46.72% of the stock is owned by corporate insiders.

NIOX Group Company Profile

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo) worldwide. Its products include NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of FeNo level in patients.